NEC Corporation (NEC; TOKYO: 6701), a company involved in IT and network technologies, has signed a strategic clinical trial collaboration agreement and an equity investment agreement with VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies.
It was reported yesterday that the contract has been signed to develop novel personalised neoantigen cancer vaccines.
According to the terms of the collaboration agreement, which is non-exclusive to both parties, NEC will provide funding for a Phase one clinical trial. Both parties will co-develop personalised cancer vaccines using NEC's artificial intelligence technology, which is used in its Neoantigen Prediction System and VAXIMM's proprietary T-cell immunotherapy technology. The vaccines are planned to be assessed in a Phase one clinical trial in various solid tumours. VAXIMM will be responsible for conducting the clinical trial, which is likely to be started in 2020. NEC has the option for development and commercialisation rights to the program worldwide, except for China and other Asian territories outside of Japan.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886